Rheumatoid arthritis (after the failure of previous anti-rheumatic drugs) - golimumab (TA225)
Fast, easy summary view of NICE guidance on 'rheumatoid arthritis'
Golimumab for the treatment of rheumatoid arthritis after the failure of previous disease-modifying anti-rheumatic drugs
NICE recommends golimumab as a possible treatment for some adults with rheumatoid arthritis in the same circumstances as other drugs for the condition (see ‘Who can have golimumab?1’ below). Golimumab for rheumatoid arthritis needs to be given in combination with a drug called methotrexate.
Who can have golimumab?1
You should be able to have golimumab therapy if:
- you have severe active rheumatoid arthritis as assessed by a rheumatologist on two separate occasions and you have already tried drugs known as 'conventional' disease-modifying anti-rheumatic drugs (or DMARDs for short), including methotrexate, but these drugs haven’t worked
- you have severe active rheumatoid arthritis and you have already tried other types of DMARDs, including a DMARD known as a tumour necrosis factor (or TNF for short) inhibitor, but these drugs haven’t worked, and you cannot take rituximab therapy for medical reasons or because you had a bad reaction to it.
Your treatment should be carried out by a specialist rheumatology team. After the first 6 months you should be able to keep having golimumab therapy only if it is clearly improving your rheumatoid arthritis. You should have check-ups every 6 months after that to make sure your golimumab therapy is still working.
1The circumstances described in this section are the same circumstances in which NICE recommends adalimumab, etanercept and infliximab (see www.nice.org.uk/guidance/TA130) and adalimumab, etanercept, infliximab, rituximab and abatacept (see www.nice.org.uk/guidance/TA195).
- TA225 Rheumatoid arthritis (after the failure of previous anti-rheumatic drugs) - golimumab: guidance (web format)
This guidance has been incorporated into the following NICE Pathways, along with other related guidance and products.
Visit the NICE Pathway: rheumatoid arthritis
- TA225 Rheumatoid arthritis (after the failure of previous anti-rheumatic drugs) - golimumab: review decision - September 2013
- TA225 Rheumatoid arthritis (after the failure of previous anti-rheumatic drugs) - golimumab: review proposal - July 2013
- Rheumatoid arthritis (after the failure of previous anti-rheumatic drugs) - golimumab: press release
This page was last updated: 13 September 2013
- Web format
- Quick reference guide (PDF)
- Full Guidance (PDF)
- TA255 Golimumab ar gyfer arthritis gwynegol: deall canllawiau NICE (fformat MS Word)
Information for the public
The summary of the key recommendations in the guidance written for patients, carers and those with little medical knowledge and may be used in local patient information leaflets.
Quick Reference Guide
The quick reference guide presents recommendations for health professionals
The published NICE clinical guidance, contains the recommendations for health professionals and NHS bodies.
The published full clinical guidance for specialists with background, evidence, recommendations and methods used.